Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Sanofi Japan Aims to Enhance Leadership Status in Diabetes Sector with GLP-1, President Says
March 14, 2013
- A Number of Blockbuster Candidates Emerging from Japanese Pharmas’ In-house R&D: Dr Nakamura of Pharma Forum Institute
March 14, 2013
- Astellas, Ambit to Terminate Development Collaboration for FLT3 Kinase Inhibitors
March 14, 2013
- Biosimilar Makers Getting Premium-Linked Inquiries from Medical Institutions
March 13, 2013
- Overseas Business Making Up for Sluggish Domestic Market; Weaker Yen Could Add Further Boost in 4th Quarter
March 13, 2013
- CSOs Diversifying Services in Japan amid Increasing Use of CMRs
March 12, 2013
- Wholesalers’ Price Negotiations Likely to Be Carried Over to New Fiscal Year; Unsettlement Rates Could Hit Double-Digit Figures
March 12, 2013
- Kyowa Kirin to Start Constructing Manufacturing Plant in Gunma in May
March 12, 2013
- Hisamitsu to File for Chronic Pain for Fentos Tape in 2013
March 12, 2013
- Nihon Chouzai Obtains Loan from Development Bank of Japan to Strengthen Production Base for Generic Drugs
March 12, 2013
- Dolutegravir Shows Significant Superior Efficacy Compared to Raltegravir in PIII Study: Shionogi
March 12, 2013
- Qol Senior Managing Director Takada Proposes Utilization of CSO for Long-Listed Products and Generics
March 11, 2013
- Nippon Shinyaku Licenses OAB Drug from DSP, Aims for Launch of Nocturia Treatment in 2019
March 11, 2013
- Takeda Files for UC and CD Drug Vedolizumab in Europe
March 11, 2013
- Otsuka, Lundbeck to Expand Collaboration, Copromote Abilify in US, Europe
March 11, 2013
- Ethical Drug Sales Up 4.8% in January: Crecon Report
March 11, 2013
- Astellas, UCB Japan Launch RA Treatment Cimzia
March 11, 2013
- NBI Calls for Proper Use of Prazaxa due to Unsatisfactory Compliance with Blue Letter
March 11, 2013
- Sandoz Will See Accelerated Growth of Japan Operations in 2013: Global Head
March 11, 2013
- Eisai to Reorganize Sales Force in Japan to Secure Aricept Market Share
March 8, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…